Clinical trials: First Pregnancy
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Medical; Abortion, Fetus
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
Comparison of rate of complete abortion between Letrozole plus Misoprostol versus Misoprostol alone in first trimester pregnancy
- Trial name
- NCT05940233
- Testing
- Letrozole
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- Queen Savang Vadhana Memorial Hospital, Thailand
Migraine Disorders
Sumatriptan and Naratriptan Pregnancy Registry
Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the peak prevalence of migraine is in women of childbearing age.
- Trial name
- NCT01059604
- Testing
- Sumatriptan, Naratriptan, Sumatriptan-naproxen combination
- Volunteers
- 868 people
- Sponsor
- GlaxoSmithKline
Helicobacter Infections, Urinary Tract Infection
First Time in Man Study of Finafloxacin Hydrochloride
The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine.
- Trial name
- NCT00483158
- Testing
- Finafloxacin hydrochloride
- Where
- Switzerland
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Antiphospholipid Syndrome
The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations
The primary objective of this study is to evaluate plasmatic concentrations of free PGF and sFlt1 for blood samples taken before a first low-molecular-weight-heparin injection and also for blood samples taken on the 4th day of…
- Trial name
- NOH-ANGIO (NCT02855047)
- Where
- France
- Volunteers
- 513 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Advanced Solid Tumor, Endometrial Carcinoma
First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
For most advanced solid tumors, current therapy is inadequate at improving quality of life, slowing progression of disease, prolonging survival, and providing a cure.
- Conditions
- Advanced Solid Tumor, Endometrial Carcinoma, Hormone Receptor Positive
- Trial name
- NP137 (NCT02977195)
- Testing
- NP137 DL and RP2D
- Where
- 3 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer.
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma
- Trial name
- NCT00004221
- Testing
- Carboplatin, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess the efficacy of atezolizumab in combination with platinum-based chemotherapy plus bevacizumab administered concurrent to chemotherapy and…
- Trial name
- ATALANTE (NCT02891824)
- Testing
- atezolizumab + avastin + platinum-based chemotherapy
- Where
- 75 sites in Austria, Belgium and 5 more
- Volunteers
- 614 people
- Sponsor
- ARCAGY/ GINECO GROUP
Recurrent Miscarriage, First Trimester Abortion
Hydroxychloroquine for Prevention of Recurrent Miscarriage.
Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation.
- Trial name
- BBQ (NCT03165136)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Ovarian Cancer
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis…
- Trial name
- TEACO (NCT00296816)
- Testing
- Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Sanofi
Primary or Secondary Infertility
Impact of Local Biopsy to the Endometrium Prior to Controlled Ovarian Stimulation on Clinical Pregnancy
In vitro fertilization (IVF) is the only available solution for many couples with various forms of infertility. The embryo implantation step in the IVF procedure is a complex multistage process and represents the majority of the…
- Trial name
- NIDABRECHE (NCT01064193)
- Testing
- biopsy, IVF
- Where
- 3 sites in France
- Volunteers
- 190 people
- Sponsor
- University Hospital, Bordeaux
Cervical Cancer
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
This is a single-arm, multicenter, phase II study to investigate efficacy and safety of Toripalimab combined with chemotherapy (paclitaxel and cisplatin) and Bevacizumab as first-line treatment in patients with recurrent…
- Trial name
- NCT04973904
- Testing
- Toripalimab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking Union Medical College Hospital
Cesarean Scar Pregnancy
Surgery Alone Versus Methotrexate Before Surgery in Cesarean Scar Pregnancy
There are no universal treatment guidelines available. The ultimate purpose of the management of CSP is to simultaneously remove the pregnancy and successfully preserve the woman's fertility (Gonzalez \& Tulandi, 2017).
- Trial name
- NCT04379219
- Testing
- Methotrexate
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Mansoura University
Pre-Eclampsia
Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester
The aims of this study are to develop algorithms based on a combination of maternal factors, uterine artery PI, MAP and serum biomarkers to estimate patient-specific risks for early Preeclampsia (PE) and to evaluate the screening…
- Trial name
- NCT02990767
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Ovarian Cancer
Platine, Avastin and OLAparib in 1st Line
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line…
- Trial name
- PAOLA-1 (NCT02477644)
- Testing
- Olaparib
- Where
- 163 sites in Austria, Belgium and 9 more
- Volunteers
- 806 people
- Sponsor
- Arcagy Research
Carcinoma, Renal Cell
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
- Trial name
- NEXTAR (NCT01508364)
- Testing
- Sorafenib (Nexavar, BAY 43-9006)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Bayer
Fallopian Tube Cancer, Ovarian Cancer
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00702299
- Testing
- cisplatin, paclitaxel, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Threatened Miscarriage
Evaluation of Serum Levels of C Reactive Protein (CRP) and Its Correlation With Fetal Ultrasound Parameters in the Prediction of Threatened Miscarriage in the First Trimester
The goal of this observational study is to evaluate and compare in pregnant women with threatened miscarriage in the first trimester.
- Trial name
- NCT06011057
- Testing
- Serum C reactive protein (CRP) level, Ultrasound
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Renal Cell Carcinoma, Clear Cell
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W)…
- Trial name
- NCT06708949
- Testing
- Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.